A Global Spotlight on CLL: Shifting Strategies and Optimizing Outcomes


Paolo Ghia, MD, PhD
Professor, Medical Oncology
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
Deputy Chairman, Experimental Oncology Division Head, B-Cell Neoplasia Unit
RCCS Ospedale San Raffaele
Milano, Italy
Jennifer R. Brown, MD, PhD
Director, CLL Center & Institute Physician Dana-Farber Cancer Institute
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology
Harvard Medical School
Boston, MA
Talha Munir, PhD
Consultant Hematologist
Leeds Teaching Hospitals NHS Trust
Leeds, UK

Statement of Need

With the treatment paradigm for chronic lymphocytic leukemia (CLL) shifting from chemoimmunotherapy to targeted agents, patients can look forward to tailored treatment strategies, improved long-term disease control and outcomes, and a better quality of life. Optimizing this new, complex therapeutic environment requires clinicians to be up-to-date on the latest guidelines and recommendations, as well as novel and emerging treatment options. Join Drs. Ghia, Brown, and Munir, as they discuss prognostic biomarkers, review guidelines and evidence supporting targeted therapies, and examine strategies for the management of patients with relapsed/refractory CLL and therapeutic intolerance. 

Engage with our experts in this 60-minute global webcast that will illuminate the integration of emerging data into everyday clinical workflows to improve therapeutic management of patients with CLL and prefigure the use of emerging therapies as availability expands across the globe. 

Learning Objectives

1. Assess testing strategies that may inform clinical decision-making in the management of CLL. 

2. Utilize updated guidelines and evidence supporting the integration of targeted agent classes in CLL as single agents or as part of combination regimens including continuous therapy, fixed-duration options, and novel combinatorial regimens.

3. Evaluate recent clinical evidence on current and emerging therapeutic approaches that have been evaluated for the treatment of patients with R/R CLL and/or therapeutic intolerance. 


Supported by

Supported through an independent educational grant from Merck.

Target Audience

Global pathologists, hematologists, medical oncologists, and secondary audiences of oncology physician associates (PAs) and nurse practitioners (NPs). 

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

American Nurses Credentialing Center

This activity is designated for 1.00 contact hour.

AMA PRA Category 1 Credit(s)™

Creative Educational Concepts, LLC, designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Declaration

Dr. Ghia reports the following financial relationships: 

Advisory Board and Consultant: AbbVie Inc.; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Loxo Oncology/Lilly; MSD; and Roche 

Grants and Research Support: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.

Dr. Brown reports the following financial relationships: 

Consultant: AbbVie Inc.; Acerta Pharma/AstraZeneca; Alloplex Biotherapeutics; BeiGene, Inc.; Genentech, Inc./Roche; Grifols Worldwide Operations; HUTCHMED; iOnctura, and Janssen Pharmaceuticals, Inc.; Kite; Loxo Oncology/Lilly; Merck & Co., Inc.; Numab Therapeutics; Pfizer Inc.; and Pharmacyclics LLC 

Research Support: BeiGene, Inc.; Gilead Sciences, Inc.; iOnctura; Loxo Oncology/Lilly; MEI Pharma, Inc.; SecuraBio, Inc.; and TG Therapeutics, Inc. 

Dr. Munir reports the following financial relationships:
Advisory Board: AbbVie Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; Janssen Global Services, LLC; Lilly; Novartis; and Sobi
Speakers Bureau: AbbVie Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; Janssen Global Services, LLC; Lilly; and Sobi

The following individuals have no financial relationships to disclose:


  • Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer review)
  • Nichole Lainhart (Planning Committee/ME)
  • Katherine Lee, PharmD (Planning Committee/MRG)
  • Susan H. Yarbrough, CHCP (Planning Committee)
  • Sandra Caballero, PharmD (Planning Committee)
  • Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com


Call us at 859-260-1717  •  info@ceconcepts.com

A Global Spotlight on CLL: Shifting Strategies and Optimizing Outcomes
Activity Date: 06/27/2023